Vanguard Personalized Indexing Management LLC Has $291,000 Stock Holdings in Merit Medical Systems, Inc. (NASDAQ:MMSI)

Vanguard Personalized Indexing Management LLC trimmed its position in Merit Medical Systems, Inc. (NASDAQ:MMSI) by 14.8% during the second quarter, HoldingsChannel.com reports. The fund owned 3,414 shares of the medical instruments supplier’s stock after selling 592 shares during the period. Vanguard Personalized Indexing Management LLC’s holdings in Merit Medical Systems were worth $291,000 at the end of the most recent quarter.

Other hedge funds have also modified their holdings of the company. Opal Wealth Advisors LLC acquired a new stake in shares of Merit Medical Systems in the 2nd quarter valued at approximately $29,000. Parallel Advisors LLC raised its position in shares of Merit Medical Systems by 114.6% in the 4th quarter. Parallel Advisors LLC now owns 397 shares of the medical instruments supplier’s stock valued at $30,000 after acquiring an additional 212 shares during the period. DekaBank Deutsche Girozentrale acquired a new stake in Merit Medical Systems during the 1st quarter worth approximately $44,000. Headlands Technologies LLC acquired a new stake in Merit Medical Systems during the 1st quarter worth approximately $50,000. Finally, GAMMA Investing LLC raised its holdings in Merit Medical Systems by 142.3% during the 2nd quarter. GAMMA Investing LLC now owns 831 shares of the medical instruments supplier’s stock worth $71,000 after buying an additional 488 shares during the period. 99.66% of the stock is currently owned by institutional investors and hedge funds.

Merit Medical Systems Price Performance

NASDAQ MMSI opened at $97.68 on Friday. The company has a quick ratio of 4.64, a current ratio of 6.24 and a debt-to-equity ratio of 0.62. Merit Medical Systems, Inc. has a 12-month low of $62.58 and a 12-month high of $101.60. The company has a market capitalization of $5.68 billion, a PE ratio of 56.14, a price-to-earnings-growth ratio of 2.52 and a beta of 0.87. The firm’s 50 day moving average is $92.98 and its 200-day moving average is $83.92.

Merit Medical Systems (NASDAQ:MMSI) last posted its quarterly earnings data on Thursday, August 1st. The medical instruments supplier reported $0.92 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.88 by $0.04. Merit Medical Systems had a net margin of 9.02% and a return on equity of 15.29%. The company had revenue of $338.00 million for the quarter, compared to the consensus estimate of $334.94 million. Equities research analysts anticipate that Merit Medical Systems, Inc. will post 3.31 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

MMSI has been the topic of several research analyst reports. Barrington Research raised their target price on shares of Merit Medical Systems from $100.00 to $114.00 and gave the stock an “outperform” rating in a report on Friday, September 20th. Bank of America raised their target price on shares of Merit Medical Systems from $92.00 to $103.00 and gave the stock a “neutral” rating in a report on Monday, September 16th. Baird R W upgraded shares of Merit Medical Systems to a “strong-buy” rating in a report on Friday, June 28th. Wells Fargo & Company raised their target price on shares of Merit Medical Systems from $85.00 to $103.00 and gave the stock an “equal weight” rating in a report on Monday, September 16th. Finally, Canaccord Genuity Group raised their target price on shares of Merit Medical Systems from $102.00 to $125.00 and gave the stock a “buy” rating in a report on Tuesday, July 2nd. Three equities research analysts have rated the stock with a hold rating, nine have assigned a buy rating and one has given a strong buy rating to the company’s stock. According to MarketBeat.com, Merit Medical Systems presently has a consensus rating of “Moderate Buy” and an average price target of $101.82.

About Merit Medical Systems

Merit Medical Systems, Inc designs, develops, manufactures, and markets single-use medical products for interventional, diagnostic, and therapeutic procedures in the United States and internationally. It operates in two segments, Cardiovascular and Endoscopy. The company provides micropuncture kits, angiographic needles, sheaths, guide wires, and safety products; peripheral intervention, including angiography, drainage, delivery systems, and embolotherapy products; spine products, such as vertebral augmentation, radiofrequency ablation, and bone biopsy systems; oncology products; and cardiac intervention products, such as access, angiography, electrophysiology and cardiac rhythm management, fluid management, hemodynamic monitoring, hemostasis, and intervention to treat various heart conditions.